Baseline metabolites could predict responders with hepatitis B virus-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet

Figure 6 Receiver operating characteristic curve of all the differential metabolites. A: Receiver operating characteristic (ROC) curve of entecavir responders (E-R) vs entecavir no-responders (E-N) (training set); B: ROC curve of FuzhengHuayu tablet (FZHY) + entecavir responders (F-R) vs FZHY + entecavir no-responders (F-N) (training set); C: ROC curve of patients vs volunteers (training set); D: ROC curve of E-R vs E-N (validation set); E: ROC curve of F-R vs F-N (validation set); F: ROC curve of patients vs volunteers (validation set). AUC: Area under the curve.